Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q2 2025 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, Aug 8, 2025
Slide 1: Q2 FY2025
(6) SANUWAVE Wound Care Technologies Q2 FY2025 August 8, 2025
Slide 2: Live Presentation and Participant Dial-in Information
Live Presentation Friday, August 8, 2025, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972b
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
3 Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectati
Slide 4: Financials Q2 2025
4 Financials Q2 2025 Consistent topline growth while managing operating costs. (in millions) Q2 2025 Q2 2024 YoY Revenue $10.2 $7.2 + 42% Gross Profit $8.0 $5.2 + 52% Gross Margin 78.3% 73.2% +513 bp Operating Expense $6.1 $3.2 +87% Revenue Gross Profit Operating Income Operating Income $1.9 $2.0 -6
Slide 5: Improved operational results
5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth in 2024 and strong year on year growth in Q2 2025. $7.0 + 37% yoy • 1,261 systems in the field at $6.0 + 10% seq end of Q2 2025 +60% yoy • In Q2 2025: 116 systems sold $5.0 + 5% seq (vs 72 in Q2 2024 and 98 in $4.0 Q
Slide 7: Q3 and FY 2025 Revenue Guidance
7 Q3 and FY 2025 Revenue Guidance Q3 2025 FY 2025 REVENUE REVENUE TARGET $12-12.7 $48-50 million Million (+47-53%) vs vs Q3 2024 REVENUE FY 2024 REVENUE of $9.36 million of $32.6 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for patients, payors, and providers. SANUWAVE is in a prime position to benefit: ▪ Approved products protected by strong IP ▪ Strong existing reimbursement with room to impr